Drugs / GSK729327
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00448890 | Nov 2006 → Dec 2008 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK729327 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00448890 ↗ |
| Action | Activate | “selective positive allosteric modulator of AMPA-type ionotropic glutamate receptors” NCT00448890 ↗ |
| Modality | Small molecule | — CHEMBL1214399 ↗ |
| Route | Oral | “repeat oral dosing of GSK729327” NCT00448890 ↗ |